Furthermore, we analyzed the correlation between tumor response and TIME characteristics, including PD‐L1 expression levels, to identify predictive biomarkers for first‐line treatment efficacy and to screen the subpopulation that could benefit from these treatments. This evidence concerns the gene CD274 and neoplasm.